ITGA4 and Duchenne muscular dystrophy: Based on the work by Pinto-Mariz et al. (2015) showing the correlation of CD49d with disease severity in DMD, we hypothesise targeting CD49d with (ATL1102) would reduce inflammation, improve muscle regeneration, reduce fibrosis and improve muscle function in dystrophic muscle (Figure 2).